drugset / Trial / NCT00671645
Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy
Phase 2
Terminated
8 enrolled
Austrian Breast & Colorectal Cancer Study Group
Hoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
* feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma * collection of response rate (T- and M-downstaging, pathological complete remission)
Timeline
- Start
- 2008-07
- Primary completion
- 2009-02-27
- Completion
- 2009-02-27
Outcome
Outcome not reported
Stopped (Enrollment): “reaching of step 1 (recruitment of 8 patients) per protocol -\> risk assessment -\> termination because of occurance of toxicity Grade 3 and 4”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Capecitabine | Small molecule | 825 mg/m2 | — |